Indeed, TREX1 is an upstream regulator of radiation-driven anti-tumor immunity (Vanpouille-Box et al., 2017) and STING is essential to promote tumor rejection in immunocompetent mice treated with the anticancer agent Topotecan (Kitai et al., 2017). Here, STING1 is linked to neoplasm.